You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
ArcherDx will develop sequencing-based circulating tumor DNA assays for use in AstraZeneca's recently launched Phase III MERMAID-1 trial of durvalumab (Imfinzi).
The Los Angeles Times writes that adaptive clinical trials may speed the search for COVID-19 treatments.
A Nature editorial calls for large, collaborative studies of potential COVID-19 treatments.
Researchers are wondering how the COVID-19 pandemic may affect results from clinical trials that continued and how to account for that influence, ScienceInsider reports.
The Shanghai-based molecular diagnostics firm is working with the Shanghai Zhongshan Hospital and other medical centers to enroll patients into the PREDICT trial.
The New York Times reports Pfizer and BioNTech have also started a trial of their mRNA-based vaccine for SARS-CoV-2 in the US.
Early trials give conflicting results on remdesivir to treat COVID-19, though a large trial suggests it shortens disease length, Nature News reports.
The companies initially plan to validate biomarkers for use with the Oncomine Dx Target Test to identify NSCLC patients for enrollment into clinical trials.
Two experimental drugs were unable to slow or prevent Alzheimer's disease among people at high genetic risk, the Associated Press reports.
Natera's Signatera test will be used to select and monitor eligible patients with KRAS-mutant tumors who have molecular residual disease after surgery.
Pfizer and BioNTech announce they are seeking FDA authorization for their candidate SARS-CoV-2 vaccine.
Science has retracted a 2007 paper from a former Dutch minister and his colleagues, according to Retraction Watch.
The New York Times reports that a plan to cull minks in Denmark to prevent the spread of a new SARS-CoV-2 strain led to calls for the prime minister's resignation.
In Science this week: winner of the Science & SciLifeLab Prize for Young Scientists, and more.